Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • MEDICAID ELIGIBILITY—D.Mass.: Court vacates Medicaid frailty rule limiting eligibility exemption
    • ADMINISTRATION OF FDC ACT—NOTICES: Issuance of priority review voucher for Emcitate
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ANTI-KICKBACK PROHIBITION—OIG ADVISORY OPINIONS: Arrangement to receive donations to offset beneficiary trust costs in the clear
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • BILLING AND CODING—OIG REPORTS: Coding errors in provider claims for Medicare Part B drugs, opportunities for improvement in CMS, MAC Oversight
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • CONTROLLED SUBSTANCES—FINAL RULES: Placement of centanafadine in Schedule III
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ELECTRONIC HEALTH RECORDS—Ill. App.: Patients failed to allege injuries traceable to transcription data breach involving Cook County Hospitals
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • END-STAGE RENAL DISEASE—FINAL RULES: CMS raises 2027 dialysis base rate, reshapes ESRD payment adjustments
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • HEALTH CARE REFORM—NOTICES: Privacy Act of 1974; Matching program
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • MEDICAL DEVICES—FINAL RULES: Classification of the spinal imaging system for neuraxial procedures
      • You have 1 more complimentary views available this month. Log in if you are already a customer
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, CONTROLLED SUBSTANCES—FINAL RULES: Placement of centanafadine in Schedule III, (Oct 30, 2026)

    By WK Editorial Staff

    Overall, the evidence from nonclinical and clinical evaluations indicates that centanafadine possesses an abuse liability lower than those of schedule II controlled substances.

    On July 24, 2026, the FDA approved a new drug application for Simtriyo (ce ...

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use